Compare D R Horton Inc (DHI) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Revvity Inc — how do they compare? D R Horton Inc trades at $150.19 (market cap $42.53B), while Revvity Inc trades at $110.91 (market cap $12.41B). The key difference: D R Horton Inc is far larger — about 3.4× Revvity Inc's market cap, and D R Horton Inc pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| DHI | RVTY | |
|---|---|---|
Market Cap | $42.53B | $12.41B |
Sector | Consumer Cyclical | Technology |
52-Week High | $184.04 | $117.75 |
52-Week Low | $129.82 | $82.26 |
Enterprise Value | $47.25B | $14.90B |
Dividend Yield | 1.2% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $148.85, down 1.8% over 24 hours, with a bearish technical signal from moving averages but oversold RSI levels. The company reported mixed quarterly earnings, beating estimates in Q4 2025 and Q1 2026 but missing in Q3 2025, with revenue declining to $34.25 billion in 2025. Analyst consensus is split between Buy and Hold ratings, with a $164.71 price target suggesting potential upside. Recent news highlights housing market headwinds from rising mortgage rates but also potential support from new legislation.
DHI presents a cautious opportunity with attractive valuation multiples (P/E 13.98, P/S 1.32) and a stable dividend, but faces risks from housing affordability pressures and volatile cash flows. Investors should weigh the company's scale and market position against macroeconomic challenges in the homebuilding sector.
RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.
The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
